When it comes to searching through the rubble of the recent cannabis crunch for the potential gemstones, Aleafia Health Inc (OTCMKTS:ALEAF) represents an increasingly interesting possibility. The stock recently bounced off a sharply rising 50-day simple moving average on increasing volume, and now sits up by more than 300% in the past 3 months, but still consolidated with possible legs above in terms of technical posture.
In addition, the company just announced, along with Guided 420 Genetics Inc. and U.S.-based AKESOgen, Inc., the commencement of a joint study on cannabinoid pharmacogenetics in medical cannabis therapy. According to the release, “The initial 200-patient study will focus on developing medical cannabis patient genetic screening tools in the areas of THC-CBD sensitivity and metabolism, Endocannabinoid Deficiency Syndrome and cannabis treatment safety and adverse event risk.”
Aleafia Health Inc (OTCMKTS:ALEAF) bills itself as a company that owns and operates a healthcare clinic that provides medical cannabis therapy to achieve optimum recovery and minimize illness and injury’s cumulative effects. The company provides medical cannabis therapy, pain management, physiotherapy, chiropractor, osteopathy, registered massage therapy, laser therapy, orthotics, and custom braces and compression socks. It provides consulting and support services for managing cannabis-sensitive cases.
The company assists rehabilitation professionals, case managers, social workers, life care planners, psychologists, family physicians, physiotherapists, litigators, and third-party insurance companies. Aleafia Inc. is based in Concord, Canada.
According to company materials, “Aleafia is a leading, vertically integrated medical cannabis company with a unique focus on delivering quality patient care from “seed” to “sale.” Aleafia is uniquely positioned with a singular focus on the medical cannabis market. The company operates the largest brick and mortar medicinal cannabis clinic network in Canada under the Canabo Medical Clinic brand, which is staffed by licensed, practicing physicians. Aleafia has obtained over 50,000 unique patients and maintains the largest medical cannabis patient data set in Canada. Aleafia’s state of the art production facilities will allow for the production of high-quality strains at low cost. Aleafia’s production will focus on securing the highest-quality medicinal product for its growing patient base.”
Find out when $ALEAF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, ALEAF just announced, along with Guided 420 Genetics Inc. and U.S.-based AKESOgen, Inc., the commencement of a joint study on cannabinoid pharmacogenetics in medical cannabis therapy. In all, we’ve witnessed 22% during the past week in terms of shareholder gains in the company.
“Aleafia is pleased to partner with G420/AKESOgen in a first of its kind cannabis related pharmacogenomics study,” said Aleafia President of Clinic Operations, Dr. Gary Goodyear. “Aleafia’s unique medical cannabis clinic business perfectly complements a robust clinical research strategy that should yield benefits to patients through the form of improved treatment methods and product development.”
Moreover, the company has witnessed a pop in interest, as transaction volume levels have recently pushed above 250% over the long run average.
“Utilizing pharmacogenetics to better manage safety and efficacy for the administration of medical cannabis in a precise manner is a large unmet need in a fast-growing industry,” added Dr. Mark Bouzyk, AKESOgen’s Chief Scientific Officer. “The combination of G420/AKESOgen’s resources and expertise in genetic analysis and genomic study management combined with Aleafia’s leading clinical footprint in Canada’s medical cannabis sector has very exciting potential for new knowledge and therapy applications in this rapidly developing field.”
Earning a current market cap value of $297.44M, ALEAF has a significant war chest ($30.3M) of cash on the books, which is balanced by about $2.2M in total current liabilities. One should also note that debt has been growing over recent quarters. ALEAF is pulling in trailing 12-month revenues of $3.1M. However, the company is seeing declines on the top-line on a quarterly y/y basis, with revenues falling at -85.5%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $ALEAF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $ALEAF, either long or short, and we have not been compensated for this article.